ストックスクリーナーアプリを入手
0.5342
5.90%
-0.0335
アフターアワーズ：
.54
0.0058
+1.09%
前日終値:
$0.5677
開ける：
$0.62
24時間の取引高:
2.00M
Relative Volume:
1.24
時価総額：
$31.41M
収益：
-
当期純損益:
$-123.46M
株価収益率:
-0.2063
EPS:
-2.59
ネットキャッシュフロー:
$-104.11M
1週間 パフォーマンス:
-36.01%
1か月 パフォーマンス:
-31.46%
6か月 パフォーマンス:
+34.32%
1年 パフォーマンス:
-13.00%
1日の値動き範囲:
$0.533
$0.62
1週間の範囲:
$0.533
$0.835
52週間の値動き範囲:
$0.2601
$1.43
Bioatla Inc Stock (BCAB) Company Profile
BCAB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BCAB
Bioatla Inc
|
0.5342 | 33.38M | 0 | -123.46M | -104.11M | -2.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Bioatla Inc Stock (BCAB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-13 | ダウングレード | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-11-13 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2022-09-15 | 開始されました | JMP Securities | Mkt Outperform |
| 2022-05-05 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2022-03-21 | 開始されました | H.C. Wainwright | Buy |
| 2021-10-15 | 再開されました | BTIG Research | Buy |
| 2021-06-28 | 開始されました | ROTH Capital | Buy |
| 2021-05-05 | 再開されました | Credit Suisse | Outperform |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2021-01-11 | 開始されました | BTIG Research | Buy |
| 2021-01-11 | 開始されました | Credit Suisse | Outperform |
| 2021-01-11 | 開始されました | JP Morgan | Overweight |
| 2021-01-11 | 開始されました | Jefferies | Buy |
すべてを表示
Bioatla Inc (BCAB) 最新ニュース
BioAtla stock slips premarket after early pop as investors weigh $40M SPV deal for phase 3 cancer trial - MSN
BioAtla and GATC Health to advance Oz-V in Phase III trial - Yahoo Finance
BioAtla announces $40 million oncology SPV investment deal - MSN
BioAtla secures $40 million for phase 3 cancer drug development By Investing.com - Investing.com Nigeria
BioAtla (BCAB) Teams Up with GATC Health for $40M SPV Transaction to Tackle OPSCC with Oz-V - parameter.io
BioAtla Stock Slips Premarket After Early Pop As Investors Weigh $40M SPV Deal For Phase 3 Cancer Trial - Stocktwits
Bioatla stock rises after $40 million SPV deal to advance cancer drug - Investing.com Nigeria
BioAtla Announces $40 Million Oncology SPV Investment Deal - TipRanks
BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle Transaction to Advance Ozuriftamab Vedotin into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma - Investing News Network
BioAtla Signs Multiple Material Agreements - TradingView — Track All Markets
BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC) - The Manila Times
BioAtla secures $40 million for phase 3 cancer drug development - Investing.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
$40M AI-driven cancer deal backs new OPSCC drug into Phase 3 test - Stock Titan
BioAtla adjourns special meeting, stockholders approve share issuance By Investing.com - Investing.com Australia
BioAtla Stockholders Approve Share Issuance, Delay Reverse Split - TipRanks
BioAtla adjourns special meeting, stockholders approve share issuance - Investing.com
BioAtla, Inc. (NASDAQ:BCAB) Sees Significant Drop in Short Interest - Defense World
Can BioAtla Inc. stock reach $100 price targetGap Up & Safe Swing Trade Setup Alerts - Улправда
Aug Drivers: Why retail investors pile into BioAtla Inc. stockInsider Selling & Weekly Watchlist of Top Performers - Улправда
How BioAtla Inc. stock performs in rising dollar environmentWeekly Trade Analysis & Technical Confirmation Trade Alerts - Улправда
Why retail investors pile into BioAtla Inc. stockTrade Volume Report & Technical Pattern Alert System - Улправда
How rising interest rates impact BioAtla Inc. stock2025 Bull vs Bear & Weekly Momentum Stock Picks - DonanımHaber
Can BioAtla Inc. stock rebound after recent weakness2025 Analyst Calls & Verified Stock Trade Ideas - Улправда
Can BioAtla Inc. stock resist market sell offsEarnings Overview Report & Daily Entry Point Alerts - Улправда
BioAtla Earnings Notes - Trefis
Acorn Capital Advisors LLC Has $1.92 Million Stock Holdings in BioAtla, Inc. $BCAB - Defense World
What drives BioAtla Inc stock priceIndustrial Stocks Review & Exceptional Capital Trading - earlytimes.in
Taking on analysts’ expectations and winning: BioAtla Inc (BCAB) - setenews.com
BioAtla (NASDAQ: BCAB) seeks approval for stock issuance and reverse split - Stock Titan
Is BioAtla Inc. stock positioned well for digital economyTrade Risk Report & Safe Entry Trade Signal Reports - Newser
Will BioAtla Inc. stock continue dividend increasesJuly 2025 Levels & Stepwise Entry and Exit Trade Signals - Newser
Why BioAtla Inc. stock is considered a top pickDollar Strength & High Return Trade Opportunity Guides - Newser
CFO Waldron Surrenders 2,371 Of BioAtla Inc [BCAB] - TradingView — Track All Markets
Officer Vasquez Surrenders 1,566 Of BioAtla Inc [BCAB] - TradingView — Track All Markets
Biotech Momentum Builds In After-Hours Trading As BioAtla, Entero, And Sonnet Climb - Nasdaq
BioAtla, Inc. (BCAB) -11.3% in Intraday Trading: What’s Driving the Move? - Stocks Telegraph
BioAtla Inc. (BCAB) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
The growth track for BioAtla Inc (BCAB) has changed recently - setenews.com
[PRE 14A] BioAtla, Inc. Preliminary Proxy Statement - Stock Titan
BioAtla Reports Q3 2025 Financial Results and Progress - MSN
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Form 424B5 BioAtla, Inc. - StreetInsider
[424B5] BioAtla, Inc. Prospectus Supplement (Debt Securities) - Stock Titan
BioAtla Secures $7.5 Million Pre-Paid Advance - TipRanks
[8-K] BioAtla, Inc. Reports Material Event | BCAB SEC FilingForm 8-K - Stock Titan
BioAtla’s New Funding: A Double-Edged Sword for Shareholders - Ad-hoc-news.de
BioAtla Agrees to $22.5 Million in Financing Agreements - MarketScreener
BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing - Investing News Network
Bioatla Inc (BCAB) 財務データ
収益
当期純利益
現金流量
EPS
0.57%
大文字化:
|
ボリューム (24 時間):